Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHA NASDAQ:MCRB NASDAQ:PEPG NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.06+2.5%$2.07$1.29▼$3.51$185.28M0.0421,789 shs13,786 shsMCRBSeres Therapeutics$20.59-2.1%$17.40$6.53▼$24.67$184.20M0.19268,113 shs264,845 shsPEPGPepGen$5.13+1.0%$1.92$0.88▼$9.94$166.62M1.969.49 million shs1.45 million shsTPSTTempest Therapeutics$10.40-3.4%$9.46$5.33▼$20.67$47.82M-2.0849,994 shs30,177 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.61%+10.43%-3.42%+10.37%-7.39%MCRBSeres Therapeutics+2.63%+11.32%+7.79%+85.29%+16.59%PEPGPepGen+7.86%-13.61%+323.33%+316.39%-43.81%TPSTTempest Therapeutics+6.11%+15.68%+5.90%+50.73%-38.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.06+2.5%$2.07$1.29▼$3.51$185.28M0.0421,789 shs13,786 shsMCRBSeres Therapeutics$20.59-2.1%$17.40$6.53▼$24.67$184.20M0.19268,113 shs264,845 shsPEPGPepGen$5.13+1.0%$1.92$0.88▼$9.94$166.62M1.969.49 million shs1.45 million shsTPSTTempest Therapeutics$10.40-3.4%$9.46$5.33▼$20.67$47.82M-2.0849,994 shs30,177 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.61%+10.43%-3.42%+10.37%-7.39%MCRBSeres Therapeutics+2.63%+11.32%+7.79%+85.29%+16.59%PEPGPepGen+7.86%-13.61%+323.33%+316.39%-43.81%TPSTTempest Therapeutics+6.11%+15.68%+5.90%+50.73%-38.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 2.00Hold$6.50215.53% UpsideMCRBSeres Therapeutics 1.60Reduce$14.33-30.39% DownsidePEPGPepGen 2.33Hold$8.4063.74% UpsideTPSTTempest Therapeutics 2.20Hold$30.00188.46% UpsideCurrent Analyst Ratings BreakdownLatest TPST, PEPG, MCRB, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MCRBSeres TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025PEPGPepGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TPSTTempest TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025PEPGPepGenStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.009/25/2025PEPGPepGenWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.009/25/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.009/24/2025MCRBSeres TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $22.009/24/2025PEPGPepGenGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.009/18/2025IPHAInnate PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/18/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$21.77M8.72N/AN/A$0.11 per share18.73MCRBSeres Therapeutics$126.32M1.43N/AN/A$1.61 per share12.79PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$5.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AMCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)PEPGPepGen-$89.98M-$2.96N/AN/AN/AN/A-92.51%-70.39%11/6/2025 (Estimated)TPSTTempest Therapeutics-$41.84M-$14.59N/AN/AN/AN/A-334.76%-130.63%11/11/2025 (Estimated)Latest TPST, PEPG, MCRB, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025TPSTTempest Therapeutics-$3.23-$2.07+$1.16-$2.07N/AN/A8/7/2025Q2 2025PEPGPepGen-$0.85-$0.70+$0.15-$0.70N/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate Pharma3.522.21N/AMCRBSeres TherapeuticsN/A1.571.57PEPGPepGenN/A4.744.74TPSTTempest TherapeuticsN/A2.122.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%MCRBSeres Therapeutics59.34%PEPGPepGen58.01%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%MCRBSeres Therapeutics4.70%PEPGPepGen5.20%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionablePEPGPepGen3032.80 million31.09 millionNot OptionableTPSTTempest Therapeutics204.44 million4.23 millionOptionableTPST, PEPG, MCRB, and IPHA HeadlinesRecent News About These CompaniesTempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | finanznachrichten.deTempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495August 11, 2025 | quiverquant.comQTempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comMorpheus-Liver Study: A New Horizon in Advanced Liver Cancer TreatmentAugust 4, 2025 | tipranks.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in ChinaJune 30, 2025 | quiverquant.comQTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comQTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer TherapyJune 6, 2025 | zacks.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPST, PEPG, MCRB, and IPHA Company DescriptionsInnate Pharma NASDAQ:IPHA$2.02 +0.01 (+0.55%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Seres Therapeutics NASDAQ:MCRB$20.59 -0.45 (-2.14%) Closing price 04:00 PM EasternExtended Trading$20.30 -0.29 (-1.41%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.PepGen NASDAQ:PEPG$5.13 +0.05 (+0.98%) Closing price 04:00 PM EasternExtended Trading$5.12 -0.01 (-0.19%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Tempest Therapeutics NASDAQ:TPST$10.40 -0.37 (-3.44%) Closing price 04:00 PM EasternExtended Trading$10.52 +0.13 (+1.20%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play General Dynamics Hits New Highs: Why It Might Keep Climbing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
